Dialog Box

Trikafta to be funded on the PBS

Trikafta has been officially funded on the PBS and will be available from Friday 1 April 2022.

Trikafta available on PBS from 1 April 2022

We are absolutely delighted to share that this morning Health Minister, Greg Hunt declared that Trikafta will be listed on the PBS.  this is indeed wonderful news. 

Trikafta has been recommended and funded for individuals 12 years and over who carry at least one f508del gene change and will be available from Friday 1 April 2022

Read more

Our next battle will be to make it available to children 6 -12 years.

We are also mindful of those families for whom Trikafta is not an option and assure the community that we will not stop fighting until there is a life saving option for all people with CF.  We will leave no-one behind.

What is Trikafta®?

Elexacaftor/tezacaftor/ivacaftor, or Trikafta®, is a type of medication known as a CFTR modulator. CFTR modulators work differently to other medications for CF. They work by correcting the malfunctioning protein that causes CF. In doing so, these medications directly address the cause of CF, rather than just the symptoms. They are not a cure, but they help the body’s cells to function more normally.

Trikafta® is a triple combination therapy. It has three active ingredients, elexacaftor, tezacaftor and ivacaftor. Elexacaftor and tezacaftor help the F508del-CFTR protein change to the correct shape, move to the surface of the cell and stay there longer. Ivacaftor then helps to open the channel so that chloride can flow in and out of the cells.

Read more about treatment 

27 March 2022
Category: News